

# Amarin Corporation

## Amarin Announces \$400,000,000 Public Offering of American Depositary Shares

July 17, 2019

BEDMINSTER, N.J. and DUBLIN, Ireland, July 17, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that it has commenced an underwritten public offering of \$400,000,000 of its American Depositary Shares pursuant to a shelf registration. All of the shares in the proposed offering are to be sold by Amarin.

Amarin intends to use the net proceeds from the offering (1) to support the ongoing and expanding commercialization of Vascepa<sup>®</sup> (icosapent ethyl) assuming the FDA approves Amarin's supplemental new drug application seeking an expanded indication for Vascepa in the United States based on the positive results of Amarin's REDUCE-IT<sup>™</sup> study, including (i) doubling the size of its existing sales force, (ii) increasing branded and non-branded advertising, and (iii) supporting its expanded commercial operations; (2) to increase commercial supply of Vascepa from third-party drug product suppliers; and (3) for general corporate purposes. Amarin also may use a portion of the net proceeds to acquire strategic assets, although it currently has no agreements or commitments in this regard.

In addition, Amarin expects to grant the underwriters a 30-day option to purchase up to an additional \$60,000,000 of its American Depositary Shares in connection with the proposed public offering. J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, Jefferies LLC and Cantor Fitzgerald & Co. are acting as the joint book-running managers in the offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

The securities described above are being offered by Amarin pursuant to a shelf registration statement on Form S-3ASR (No. 333-216385) previously filed with the Securities and Exchange Commission (the "SEC") on March 1, 2017 and automatically became effective upon filing. The securities may be offered only by means of a written prospectus, including a prospectus supplement, forming a part of the effective registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website at [www.sec.gov](http://www.sec.gov). Copies of the preliminary prospectus supplement relating to these securities may be obtained for free by visiting EDGAR on the SEC's web site at [www.sec.gov](http://www.sec.gov). When available, copies of the final prospectus supplement and the accompanying prospectus may also be obtained by contacting J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717; or by telephone at (866) 803-9204; or by email at [prospectus-eq\\_fi@jpmchase.com](mailto:prospectus-eq_fi@jpmchase.com), Goldman Sachs & Co. LLC, 200 West Street, New York, New York 10282, Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone: (877) 547-6340 or email: [Prospectus\\_Department@jefferies.com](mailto:Prospectus_Department@jefferies.com) or Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Avenue, 6th Floor, New York, NY 10022; or by email at [prospectus@cantor.com](mailto:prospectus@cantor.com).

This news release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

### About Amarin

Amarin Corporation plc. is a rapidly growing, innovative pharmaceutical company focused on developing therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in polyunsaturated fatty acids and lipid science. Vascepa (icosapent ethyl) is Amarin's first FDA-approved drug and is available by prescription in the United States, Lebanon and the United Arab Emirates. Amarin's commercial partners are pursuing additional regulatory approvals for Vascepa in Canada, China and the Middle East. For more information about Amarin, visit [www.amarincorp.com](http://www.amarincorp.com).

### Disclosure Notice

*This press release contains forward-looking statements, within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements related to Amarin's proposed public offering of American Depositary Shares and the FDA's evaluation of Amarin's pending supplemental new drug application, are forward-looking statements that involve risks and uncertainties. Words such as "intends," "plans," "expects," "may," "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are not promises or guarantees. These forward-looking statements are based upon Amarin's current expectations. Actual events and results and the timing of events and results could differ materially from those anticipated in such forward-looking statements. Among the factors that could cause actual results to differ materially from those described or projected herein are the following: risks related to the underwriters' consummation of their obligation to purchase the securities, whether Amarin will be able to satisfy its obligations to close the offering and the risk that Amarin will not use the proceeds from the offering in the manner contemplated, as well as the risks, uncertainties and other matters detailed in Amarin's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K, its most recent Quarterly Report on Form 10-Q and the preliminary prospectus supplement relating to the offering. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they were made. Amarin undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise, except as required by law.*

### Amarin contact information:

#### Investor Relations:

Elisabeth Schwartz  
Investor Relations and Corporate Communications  
Amarin Corporation plc  
In U.S.: +1 (908) 719-1315

[investor.relations@amarincorp.com](mailto:investor.relations@amarincorp.com)

Lee M. Stern  
Trout Group  
In U.S.: +1 (646) 378-2992  
[lsfern@troutgroup.com](mailto:lsfern@troutgroup.com)

*Media Inquiries:*

Gwen Fisher  
Corporate Communications  
Amarin Corporation plc  
In U.S.: +1 (908) 325-0735  
[pr@amarincorp.com](mailto:pr@amarincorp.com)